Great progress has been made in the treatment of acute lymphocytic leukemia (ALL), primarily owing to the development of targeted therapies such as monoclonal antibodies and tyrosine kinase inhibitors. The use of targeted therapies has significantly improved survival outcomes for patients with ALL and has become a mainstay of frontline treatment. Since the FDA approval of blinatumomab, inotuzumab ozogamicin, and tisagenlecleucel, clinical trials have been increasingly investigating combination regimens with these targeted agents with the goal of optimizing their use and reducing the need for cytotoxic therapies.
In today’s podcast, Bijal Shah, MD, of the H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, Daniel W. Lee, MD, of the University of Virginia, Charlottesville, VA, Nicholas Short, MD, of the MD Anderson Cancer Center, Houston, TX, and Robin Foà, MD, of the Sapienza University of Rome, Rome, Italy, talk on the latest clinical updates on the use of targeted therapies for the treatment of ALL, as presented at the European Hematology Association (EHA) Congress 2021.
The Lymphoma Sessions: highlights from ASH 2020
The MDS Sessions: Giants in MDS
Latest therapies in AML: IMGN632, magrolimab & gilteritinib
VJSession: EBMT/EHA CAR-T Nursing Session
The Myeloma Sessions: key updates from ASH 2020
The MPN Sessions: Rapidly advancing genomic discoveries and treatment strategies in MPNs
Updates for the management of MDS from ASH 2020
The AML Sessions: highlights from ASH 2020
The MDS Sessions: treating MDS around the world
Advances in the amyloidosis space: Prognostic factors, CAEL-101 immunotherapy and real-world data
Developments in CLL: MRD, LOXO-305 and venetoclax at ASH 2020
Myeloma at ASH 2020: talquetemab, CARTITUDE-1 & highlights
Advances in CAR T-cell therapies for lymphoma from ASH 2020
Moving forward in MPN: timing driver mutations and novel therapies from ASH 2020
The MDS sessions: lower-risk disease
The AML Sessions: FLT3-mutated disease
The Lymphoma Sessions: highlights from iwNHL 2020
The MDS sessions: clinical trial participation, endpoints & approvals
The AML sessions: venetoclax-based regimens
The AML Sessions: IDH inhibitors
Create your
podcast in
minutes
It is Free
Good Mood Revolution
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
Precision Medicine Forum Podcast
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive